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Abstract  
Chinese hamster ovary (CHO) cells are the preferred cell factory for the production of therapeutic 
glycoproteins. Although efforts primarily within bioprocess optimization have led to increased 
product titers of recombinant proteins (r-proteins) expressed in CHO cells, post-transcriptional 
bottlenecks in the biosynthetic pathway of r-proteins remain to be solved. To this end, the ectopic 
expression of transgenes (effector genes) offers great engineering potential. However, studies on 
effector genes have in some cases led to inconsistent results. Whereas this can in part be attributed 
to product specificity, other experimental and cellular factors are likely important contributors to 
these conflicting results. Here, these factors are reviewed and discussed with the objective of 
guiding future studies on effector genes. 
Keywords: Cell engineering, Chinese hamster ovary (CHO) cells, ectopic expression, endoplasmic 
reticulum, ER stress, gene dosage, product quality, recombinant protein production, secretion 
bottleneck, specific productivity
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1. Introduction 
Chinese hamster ovary (CHO) cells are the most frequently used cell host for biopharmaceutical 
production of glycoproteins (Walsh, 2014). Besides being the host cell used for the first approval of 
a recombinant biopharmaceutical produced in mammalian cells in 1986 (Wurm, 2004), CHO cells 
are the preferred choice for a number of reasons. First, CHO cells can easily be adapted for high-
density suspension growth in a chemically defined, serum-free medium in large-volume cultures 
(Kim et al., 2012; Sinacore et al., 2000). Second, gene amplification methods have been established 
for CHO cells, leading to high specific productivity (qp) of recombinant protein (r-protein) in stable 
cell lines (Durocher and Butler, 2009). Third, CHO cells are less prone to virus infection than other 
mammalian production cell lines and are therefore regarded as a safe host for the production of 
human therapeutics (Berting et al., 2010). Last, CHO cells and other mammalian cells are the 
platform of choice for the production of human recombinant glycoproteins because of their ability 
to correctly make human-like post-translational modifications (PTMs), in particular glycosylation 
(Butler and Spearman, 2014). Human-like PTMs turn r-protein products into functional drug 
molecules with reduced immunogenicity, prolonged serum half-life and high pharmacological 
efficacy in the human body (Walsh and Jefferis, 2006). 
The production of r-proteins in CHO cells in optimized bioprocesses can reach qp of 50–90 pg 
per cell per day (pcd) (Hacker et al., 2009). As previously pointed out by Khan and Schröder 
(2008), professional secretory plasma cells are capable of secreting IgM at a rate of 200–400 pcd 
(Fazekas et al., 1980; Randall et al., 1992). This clearly indicates that nature’s physiological limit 
not yet has been reached and thus, intracellular rate-limiting steps in protein production remain to 
be resolved. Indeed, post-transcriptional rate-limiting steps in the biosynthetic pathway of r-proteins 
have been reported multiple times in CHO cells (Johari et al., 2015; Kallehauge et al., 2016; S. J. 
Kim et al., 1998; Ku et al., 2008; Schröder et al., 1999) as well as in other mammalian cells (Barnes 
et al., 2004; Fann et al., 1999). The presence of a post-transcriptional bottleneck suggests that there 
are many opportunities to improve the secretory pathway machinery in CHO cells. Moreover, 
artificial protein scaffolds such as fusion proteins are becoming more popular in the 
biopharmaceutical industry with increasing market shares (Aggarwal, 2014). These non-native 
scaffolds are in general more prone to misfolding (Lee et al., 2007). Thus, the cost-efficient 
production of these difficult-to-express fusion proteins will most likely require substantial 
engineering of the folding machinery in the secretory pathway. 
Engineering CHO cells by the ectopic expression of transgenes (hereafter referred to as effector 
genes) is an attractive solution to improve the secretory capacity of CHO cells. In many cases, such 
engineering efforts have led to positive effects on qp on a variety of r-proteins (see recent reviews 
(Fischer et al., 2015; Hussain et al., 2014; Nishimiya, 2013)). This multitude of studies showing 
positive effects clearly underpins the potential of modulating the expression of effector genes. 
However, as previously pointed out (Hussain et al., 2014; Kim et al., 2012; Mohan et al., 2008), 
some effector genes are flawed by inconsistent effects. To exemplify this, all published studies on r-
protein productivity (volumetric productivity or qp) in CHO cells with the ectopic expression of the 
widely studied protein disulphide isomerase (PDI) are listed in Table 1. PDI is an endoplasmic 
reticulum (ER)-resident enzyme conferring disulphide isomerase activity (Hatahet and Ruddock, 
2009). Moreover, PDI forms and reduces disulphide bonds in nascent polypeptides in the lumen of 
the ER and in parallel inhibits the aggregation of folding intermediates through its function as a 
chaperone (Appenzeller-Herzog and Ellgaard, 2008). The reported effects of overexpressing PDI on 
volumetric productivity and qp vary from a two-fold decrease through no effect to a 1.4-fold 
increase. This inconsistency, can to some extent, be explained by product specificity, as several 
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different r-proteins have been used as model proteins. In fact, PDI overexpression only increased qp 
for one of four monoclonal antibody (MAb) variants in a parallel experimental setup (Pybus et al., 
2014). However, many cellular and experimental factors are at play when examining how an 
effector gene affects volumetric productivity and qp (Fig. 1). Thus, it is likely that factors other than 
product specificity are involved in the inconsistency of PDI’s effect on volumetric productivity and 
qp of r-proteins.  
In contrast to PDI, the effect of many effector genes on volumetric productivity or qp has only 
been reported once (Hussain et al., 2014; Nishimiya, 2013). Notwithstanding product specificity, it 
is likely that a considerable number of these effects are conditional – for example, specific to the 
monoclonal cell line or the expression platform being used. The applicability of such conditional 
effects is often limited to the research group in question and not to the CHO engineering field in 
general. Here, cellular and experimental factors that potentially affect the outcome when studying 
effector genes will be described and discussed. If these factors are appreciated, the risk of 
unintentionally investigating conditional effects can be minimized and the chance of finding true 
positive effects can be increased. 
 
2. CHO host cell lines 
In 1957, the immortalized, original CHO cell line (the common ancestor for all CHO cell lines) 
was established from the ovaries of an outbred female Chinese hamster (Puck, 1957; Wurm, 2013). 
This original cell line has led to a multitude of commercially available and proprietary CHO cell 
lines (Wurm, 2013). Being an immortalized cell line, the genome of CHO cells is inherently 
unstable (Frye et al., 2016). Moreover, dihydrofylate reductase deficiency (DHFR) in the widely 
used DXB11 and DG44 cell lines was achieved by subjecting cells to radiation- and chemical-
mediated mutagenesis (Urlaub et al., 1983; Urlaub and Chasin, 1980). Thus, host CHO cell lines 
constitute a genomically diverse family in terms of single nucleotide polymorphisms (Lewis et al., 
2013), copy-number variations (Kaas et al., 2015) and karyotypes (Wurm and Hacker, 2011). 
Moreover, it has recently been suggested to regard CHO host cell lines as ‘quasispecies’, 
emphasizing the extensive genetic heterogeneity residing in the CHO host cell family (Wurm, 
2013).  
When CHO host cell lines are compared, they are found to be not only genetically divergent but 
also phenotypically diverse. For example, it has been shown that the ER size in the CHO-K1 host 
cell line is larger compared to a DXB11-derived host cell line, and the mitochondrial mass was also 
found to be higher in CHO-K1 cells (Hu et al., 2013). These phenotypic differences could explain 
the approximately 10-fold lower qp observed for the DXB11-derived host cell line compared to 
CHO-K1 cells, which was obtained for two different MAbs from stable gene-amplified clones (Hu 
et al., 2013). In a recent CHO bibliome study by Golabgir et al. (2016), a meta-analysis of 
bioprocess studies showed that the cell growth rate and qp of DXB11- compared to DG44-derived 
cell lines were significantly higher and lower, respectively. Although the bibliome data consist of a 
range of process conditions and experimental setups, both DG44 and DXB11 are DHFR-deficient 
cell lines. Consequently, the gene-amplification process and clone selection are therefore 
comparable, warranting the comparison of qp. Moreover, CHO-K1-derived cells were found to 
grow slower than DG44-derived cells in the bibliome study. The observed differences between 
CHO-K1, DXB11 and DG44 host cells clearly illustrate the phenotypic diversity that resides within 
the family of CHO host cells.  
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Being such a diverse family of cell lines, the following question arises: Are effects on qp of an 
effector gene transferable across CHO host cell lines? In the PDI example, at least four CHO host 
cell lines (DXB11, DG44, CHO-K1 and CHO-S) have been used (Table 1). Because of product 
specificity and other factors, it is not possible to make any conclusion on the influence of CHO host 
cell lines on PDI as an effector gene. As for the spliced form of X-box-binding protein 1 (XBP-1S), 
it has been shown that ectopic XBP-1S expression was able to increase the volumetric productivity 
of erythropoietin (EPO) in CHO-K1 as well as in the murine NS0 myeloma cell line (Ku et al., 
2008). Moreover, Tastanova et al. (2015) found that the CHO-derived transcription factor Yin Yang 
1 (YY1) improved the volumetric productivity of a MAb (Rituximab) upon co-transfection in a 
transient expression setup in CHO-K1 and CHO-S cells. Moreover, YY1 expression also improved 
the volumetric productivity of MAb in DG44- and DXB11-derived stable cell lines. In a transient 
expression setup using the human orthologue, the positive effect of YY1 on volumetric productivity 
was also observed in human embryonic kidney (HEK) cells, human cervical cancer cells (HeLa) 
and human fibrosarcoma cells (HT-1080), which are immortalized cell lines with genomes vastly 
different from CHO cells. Future studies will show whether the generic effect of YY1 and XBP-1S 
between genomically distinct cell lines is an exception that proves the rule. 
 
3. Clonal variation 
Phenotypic heterogeneity is observed not only between CHO host cell lines but also within the 
cell population of CHO host lines. In fact, CHO cells are known for being able to adapt to changes 
in process conditions, which has been exploited in the industry to generate clonally derived cell 
lines with enhanced manufacturing capabilities (Frye et al., 2016). Moreover, the majority of cells 
in host cell lines seem to be intrinsically incapable of high production of MAb, and universally 
competent cells are likely relatively rare cases (O’Callaghan et al., 2010). Functional heterogeneity 
residing in the host cell population is typically referred to as clonal variation (Fig. 2). Although not 
CHO cells, how clonal variation is generated (phenotypic drift) has been elegantly demonstrated in 
the murine cell line NS0 (Barnes et al., 2006). Three rounds of limiting dilution were performed, 
and variation in cell growth rate was observed after each round of subcloning. This phenomenon 
has subsequently been observed in subclones of a CHO-K1-derived host cell line (Davies et al., 
2013). The cell growth rate changed for approximately half of the clones during extended culture 
time, demonstrating that both static (inheritable) phenotypes and phenotypic drift were observed. 
Moreover, the initial cell growth rate of the subclones varied substantially, which demonstrates the 
presence of clonal variation within the host cell line. When analysing single cells in a monoclonal 
cell line culture, large variation in transgene expression has been observed, which could not be 
attributed to variables such as cell cycle and cell size (Pilbrough et al., 2009). Since this variation 
was shown to fluctuate within a relatively short period, phenotypic drift may partly originate from 
non-genetic diversity. However, a comprehensive genome and epigenome characterization of a 
CHO-K1 host cell line adapted to growth in three different media showed high variation in genome 
sequence both as a result of media adaptation and under constant culture conditions over time 
(Feichtinger et al., 2016). Based on these observations and as previously stressed by Frye et al. 
(2016), absolute genetic homogeneity in a cell culture does not seem achievable because of the 
genomic plasticity inherent in immortalized mammalian cell lines. 
Clonal variation for recombinant CHO cell lines does not originate only from functional 
heterogeneity in the host cell line, as genetic heterogeneity is also introduced during the generation 
of recombinant cell lines (Fig. 2). For example, chromosomal aberrations were observed in 10 of 16 
stable gene-amplified GFP-expressing cell lines not observed in the DG44 host cell line (Derouazi 
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et al., 2006). In addition, significant differences in specific growth rate and qp of subclones from a 
gene-amplified MAb-producing clonally derived DG44 CHO cell line have been observed (N. S. 
Kim et al., 1998). Thus, recombinant monoclonal cell lines generated by gene amplification are 
genetically and phenotypically diverse.  
Does an observed phenotypic difference between two recombinant cell lines originate from 
clonal variation or from stable expression of an effector gene? If only one control cell line and one 
effector gene-expressing cell line (both monoclonal) are being investigated, it is not possible to rule 
out that an observed phenotypic difference originates from clonal variation (Stockholm et al., 2007). 
Instead, this would require a number of monoclonal cell lines in both categories to demonstrate that 
the difference is a consequence of expressing the effector gene. In the PDI example, only single 
clonally derived producer cell lines have been used as host cell lines when analysing the effect of 
constitutively expressing PDI (Table 1). These monoclonal producer cell lines have then been used 
as hosts to generate either quasi-monoclonal or mono-monoclonal PDI-expressing lines (see Fig. 2 
for definitions). Thus, the observed effects of PDI expression are likely biased by clonal variation, 
as quasi-polyclonal and mono-monoclonal cell lines in general do not represent the average 
phenotype in the host cell line. This bias can be addressed if employing polyclonal producer cell 
lines (see ‘Clonality and clonal variation’ in section 7). 
In summary, caution must be exercised when investigating the effects of expressing effector 
genes in clonally derived producer cell lines. At a minimum, quasi-polyclonal or mono-monoclonal 
cell lines from two but preferably three different monoclonal producer cell lines should be 
examined. Alternatively, transient expression or stable episomal expression of the r-protein product 
circumvents the bias originating from clonal variation (see section 7). 
 
4. Effector gene origin 
The main application of CHO cells in the biopharmaceutical industry is to produce human-like 
glycoproteins. Although humanized, some MAb biopharmaceuticals are chimeric molecules of 
mouse and human amino acid sequences (Ahmadzadeh et al., 2014). Thus, human and, to some 
extent, murine-derived polypeptide sequences are expressed in a heterologous CHO-based context. 
In view of this, should the origin of an effector gene be human, CHO or mouse? In the PDI example 
(Table 1), all three origins have been reported, although human PDI is overrepresented (four of six 
studies). This observation is consistent with an overall preference for the human origin of effector 
genes (Fischer et al., 2015).  
The argument for using a human effector gene would be that the effector gene protein is 
expected to directly interact with the r-protein. In other words, it is thought to facilitate a favourable 
interaction between two autologous (human) molecules that is less likely to take place between two 
heterologous molecules (direct effect; see Fig. 1). In contrast, the argument for using a CHO 
effector gene would be that an effector gene is expected to interact with host cell molecules 
(indirect effect through element X; see Fig. 1). For example, an effector gene-encoded transcription 
factor and a chaperone are expected to interact with host cell molecules (DNA) and the r-protein, 
respectively. Thus, the choice of effector gene origin depends on the function of the effector gene.  
The influence of effector gene origin on CHO cell line engineering has not been systematically 
investigated. However, it has been shown that both CHO- and human-derived PDI can improve qp 
of human MAb-related r-proteins in CHO cells (Johari et al., 2015; Mohan et al., 2007; Pybus et al., 
2014) (Table 1). Moreover, XBP-1S has been shown to increase volumetric productivity and qp in 
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CHO cells – both the human (Becker et al., 2008; Cain et al., 2013; Pybus et al., 2014) and murine 
(Hansen et al., 2015; Ku et al., 2008) orthologues. In contrast, only the CHO-derived and not the 
human orthologue of YY1 was able to increase volumetric productivity in CHO cells and vice versa 
in human cells (Tastanova et al., 2015). As pointed out by the authors, this clearly indicates that 
interaction with host-specific co-factors was required. 
Although there might be a few cases where a human effector gene orthologue is needed, CHO 
orthologues are more likely to be functional because they will be present in a non-foreign 
(autologous) cellular context like YY1. Thus, using CHO-derived effector genes likely increases the 
chances of identifying true positive effects and at the same time minimizing the risk of false 
negative effects. Furthermore, applying CHO-derived effector genes would enable direct 
comparisons of the expression level between the recombinant effector gene and the endogenous 
gene. Accordingly, this would entail comparisons of effector gene doses across experiments and 
studies (see section 6). 
Cloning CHO and Chinese hamster gene sequences has recently become a more straightforward 
task owing to the drafts of Chinese hamster and CHO cell line genomes (Brinkrolf et al., 2013; 
Lewis et al., 2013; Xu et al., 2011). Moreover, efforts to improve the quality of the Chinese hamster 
genome and to refine annotations are currently ongoing (Kremkow et al., 2015). The availability of 
correctly annotated Chinese hamster gene sequences is likely to facilitate the autologous, ectopic 
expression of effector genes in CHO cells in future CHO cell line engineering studies. 
 
5. Secretion bottleneck and ER stress 
A non-linear relationship between the transcript level and qp in CHO cells shows that there is a 
post-transcriptional bottleneck in the biosynthetic pathway of r-proteins. Such a bottleneck has been 
reported in CHO cells upon transient expression of an Fc-fusion protein (Johari et al., 2015) and 
EPO (Ku et al., 2008), although only EPO titer and not qp was reported for the latter example. In 
addition, a post-transcriptional bottleneck has been reported in stable MAb-producing CHO cells (S. 
J. Kim et al., 1998) and NS0 myeloma cells (Barnes et al., 2004). Moreover, a post-translational 
rate-limiting step (hereafter referred to as a ‘secretion bottleneck’; Fig. 3A) has been demonstrated 
in stable CHO cell lines expressing antithrombin III (Schröder and Friedl, 1997) as well as in baby 
hamster kidney cells constitutively expressing activated protein C (Fann et al., 1999). In these two 
cases, a non-linear relationship between the intracellular level of r-proteins and qp was observed, 
which demonstrates that the bottleneck was downstream of translation and translocation and 
therefore within the secretory pathway (ER, Golgi and secretory transport vesicles). Most 
intracellular whole MAb molecules in stable CHO cell lines have been found to be in the early part 
of the secretory pathway (between ER and cis-Golgi) for cell lines with and without a secretion 
bottleneck (O’Callaghan et al., 2010). The study by O’Callaghan et al. also demonstrated that 
bottlenecks in the biosynthetic pathway of the same MAb molecule are cell line-specific, 
irrespective of qp. For example, in one cell line with qp of 7 pcd, the folding and assembly rate of 
MAb was particularly slow, whereas in another cell line with qp of 8 pcd, secretion was the rate-
limiting step. 
The unfolded protein response (UPR) is a homeostatic transcriptional program that is induced 
when the capacity of folding and processing incoming nascent polypeptides in the ER is exceeded 
(Moore and Hollien, 2012; Walter and Ron, 2011). This protein folding perturbation is called ER 
stress. If high levels of ER stress conditions persist, the UPR will eventually become pro-apoptotic 
(Jäger et al., 2012; Moore and Hollien, 2012; Sano and Reed, 2013). ER stress originating from r-
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protein expression has been observed several times. For example, qp of certain r-proteins has been 
shown to correlate with ER stress levels upon transient expression (Johari et al., 2015; Ku et al., 
2010). Once post-transcriptional and/or secretion bottleneck conditions were established, ER stress 
levels increased abruptly upon a higher expression level of r-protein (Fig. 3B). Moreover, cell lines 
expressing seemingly difficult-to-express r-proteins have been shown to have increased levels of 
ER stress compared to cell lines expressing easy-to-express r-proteins (Johari et al., 2015; Le Fourn 
et al., 2014; Sommeregger et al., 2016). These examples show that ER stress and secretion 
bottlenecks are intimately linked.  
In two studies by Ku et al., a post-transcriptional bottleneck was identified at high gene doses of 
transiently expressed EPO (Ku et al., 2010, 2008). Ectopic expression of XBP-1S was found to 
improve the volumetric productivity of EPO only at gene doses causing ER stress and with a post-
transcriptional bottleneck phenotype (Ku et al., 2008). Consequently, some ER-related effector 
genes – such as XBP-1S – can improve volumetric productivity and/or qp only in conditions where 
a post-transcriptional bottleneck is present (Fig. 3A). Being an ER-localized protein, the effects of 
PDI on qp likely depend on whether such bottlenecks are present. However, the presence of a post-
transcriptional bottleneck has been investigated for only two of eleven r-proteins (Table 1). 
Preferably, non-secretion bottleneck as well as secretion bottleneck conditions should be established 
when analysing effector genes, which would minimize the risk of obtaining false negative results. 
Indeed, an inadequate conclusion would have been drawn if only a low gene dosage of EPO had 
been used by Ku et al. (2008).  
Obtaining positive effects on qp of effector genes in conditions without post-transcriptional 
bottlenecks is an interesting supposition. To the knowledge of the authors, no studies have 
methodically investigated this topic. Although not investigated, it seems likely that a post-
transcriptional bottleneck was not present when expressing Rituximab in CHO-S cells in the study 
by Tastanova et al. (2015), as we have obtained a >10-fold higher qp in a comparable transient 
expression setup in shake flasks (Hansen et al., 2015). Nevertheless, a three-fold increase in 
Rituximab titer was obtained upon YY1 overexpression in CHO-S (Tastanova et al., 2015). In a 
stable CHO-DG44-derived clone expressing MAb, the positive effect of YY1 was also observed, 
and this effect could not be ascribed to an increase in the cell growth rate or transcript level of MAb 
heavy and light chains. The increase in qp combined with an unchanged transcript level suggests 
that the secretion rate per transcript must be three-fold higher, indicating that the effect is post-
transcriptional. Differences in the translation rate have been predicted between stable monoclonal 
CHO cell lines expressing the same MAb by mathematical modelling (O’Callaghan et al., 2010), 
suggesting that the effect of YY1 could be an increased translation rate. Alternatively, it could be a 
decreased degradation of folding intermediates mediated by the ER-associated degradation pathway 
(Hussain et al., 2014; Merulla et al., 2013) or autophagy- and lysosomal-mediated degradation (Kim 
et al., 2013). Nevertheless, the YY1 example implies that a secretion bottleneck phenotype does not 
seem to be a prerequisite for improving qp. 
 
6. Effector gene dosage 
Whether an effector gene is able to improve qp depends not only on the presence of the effector 
gene-encoded protein but also on the expression level. In other words, the outcome of expressing an 
effector gene on qp depends on the effector gene dosage (Brown and James, 2015; Xiao et al., 
2014). In a study by Davis et al. (2000), CHO clones stably expressing an Fc-fusion protein with 
different expression levels of PDI (‘low PDI’, ‘medium PDI’ and ‘high PDI’) were used (Table 1). 
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Whereas the low PDI clone had no apparent effect on product titer, the medium PDI had increased 
intracellular levels of the Fc-fusion protein but no effect on titer and the high PDI clone had 
increased intracellular levels of Fc-fusion protein and a two-fold decrease in titer. If leaving clonal 
variation out of consideration, this example shows that the folding machinery can be overwhelmed 
when an ER-localized enzyme exceeds an optimal expression level range. Like ER-resident 
enzymes, gene dosage titration is also important when investigating transcription factors as effector 
genes. Johari et al. (2015) observed increased volumetric productivity of two MAb variants when 
expressing either XBP-1S or cleaved activating transcription factor 6 (ATF6c) at lower gene doses 
and no effect at the highest gene dosage. Moreover, the gene dosage for both effector genes 
inversely correlated with cell growth, suggesting that the expression of XBP-1S and ATF6c 
generated a fitness cost. When Tastanova et al. (2015) investigated how the gene dosage of the 
transcription factor YY1 affected the volumetric productivity of a variety of MAb molecules and 
CHO cell lines, an optimal gene dosage range of YY1 was observed. These examples demonstrate 
the importance of gene dosage titration. 
Two complementary strategies were employed to titrate the YY1 gene dosage by transient 
expression: the filler plasmid (empty vectors) principle and promoters with different strengths 
(Tastanova et al., 2015). Filler plasmids are used to titrate the effector gene-encoding plasmid 
(Estes et al., 2015; Rajendra et al., 2015, 2012), whereas promotors with different strengths drive 
transcription at different rates (Brown and James, 2015; Qin et al., 2010). The filler plasmid 
principle is a cost-efficient solution in transient expression-based setups, as no additional cloning 
work is needed besides a single plasmid preparation of the filler plasmid. Moreover, a linear 
relationship between the transfected plasmid load and mRNA can be expected at relatively low gene 
doses (Johari et al., 2015; Ku et al., 2008; Rajendra et al., 2015). When controlling the expression 
level of stably integrated effector genes, using a set of promotors with different strengths is the 
preferred choice (Brown and James, 2015). 
Only a single gene dosage has been used when investigating the effect of PDI expression on 
nine of eleven r-proteins (Table 1). This means that, in nine of eleven cases, it is unknown whether 
an optimal or adverse gene dosage was used. This indicates that a substantial number of studies on 
ectopic expression of effector genes have only employed a single gene dosage, suggesting that the 
gene dosage space for many studied effector genes remains to be explored.  
In summary, a wide range of effector gene doses should preferably be used in the attempt to find 
an optimal range of expression. Moreover, the expression level of the effector gene and the 
endogenous gene should be compared to facilitate comparisons across studies, which requires that 
CHO-derived effector genes be used (see section 4). These efforts would facilitate higher chances 
of drawing valid conclusions as well as higher chances of identifying conditions where effector 
genes improve qp. 
 
7. Expression platforms  
There are several different platforms for the ectopic expression of r-proteins in CHO cells. r-
proteins can be expressed either transiently from a non-integrated plasmid or from a gene stably 
integrated into the genome. Transient gene expression (TGE) is a widely used technology for the 
rapid production of r-proteins, usually during a 2-10 day batch or fed-batch process (Baldi et al., 
2007). TGE is the preferred production method during the early stages of drug development for 
preclinical studies, as a sufficient quantity of r-protein can be obtained within a short period of time 
(Kim et al., 2012). However, the lower protein yield achieved with TGE in CHO cells has 
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historically been a major drawback compared to the substantially higher yields obtained with stable 
gene expression (SGE). Thus far, extensive efforts to improve TGE yields in CHO cells have been 
made by optimizing the culture environment (Galbraith et al., 2006; Ye et al., 2009), transfection 
efficiency (Mozley et al., 2014; Rajendra et al., 2015, 2012), vector systems (Cho et al., 2001; 
Mariati et al., 2010) and host cell line (Cain et al., 2013; Daramola et al., 2014; Macaraeg et al., 
2013). Therefore, TGE has become a robust and flexible system, applicable to multiple r-proteins, 
expression volumes and bioprocesses with substantially increased yields of up to 3 g/L for MAb-
producing CHO cells (Liu et al., 2015).  
SGE is a prerequisite for the stable, large-scale manufacturing of r-proteins as biologics for 
clinical applications (Noh et al., 2013; Wurm, 2004). Stable cell lines are typically generated using 
selection based on a selective marker expressed on the same plasmid as the r-protein (Priola et al., 
2016). If desired, the gene encoding the r-protein can be amplified to increase qp, although gene-
amplification in general reduces the stability of volumetric productivity and qp in extended culture 
conditions (Chusainow et al., 2009). The two most widely used gene amplification systems are the 
DHFR system and the glutamine synthetase system (Noh et al., 2013). Nowadays, companies report 
titers of >10 g/L for MAb production (Gronemeyer et al., 2014). As an alternative to random 
transgene integration, piggyBac or sleeping beauty-mediated transposition can be used, where 
transgene integration into highly transcribed regions of the host genome is favoured. This leads to a 
generally higher rate of transgene transcription compared to the random integration of plasmids 
(Ding et al., 2005; Galvan et al., 2009; Wilson et al., 2007). Consequently, higher qp and stability 
compared to stable producer clones obtained by random integration have been achieved with MAb 
titers of up to 7.6 g/L (Matasci et al., 2011; Rajendra et al., 2016). 
Inducible expression (IE) platforms support the idea of a regulated, biphasic r-protein 
expression throughout the production phase, e.g., being turned off during growth and turned on only 
during the late exponential and stationary phase. The inducible nature of the IE platform provides a 
powerful expression system for r-proteins that might confer toxicity when being expressed by 
constitutive promoters. Several systems with either repressor or activator configurations have been 
developed for mammalian cells to achieve tight control of gene expression. Among many, there are 
i) antibiotic-based regulation systems, such as the Tet-Off-On system regulated by tetracyclin 
(Gossen and Bujard, 1992; Mohan et al., 2007), the Pip system regulated by streptogramin 
(Fussenegger et al., 2000) and the E.REX system regulated by macrolides (Weber et al., 2002); ii) 
an aptamer-based regulation system (Werstuck and Green, 1998); and iii) the cumate gene-switch 
(Gaillet et al., 2010; Mullick et al., 2006). All these inducible systems have been successfully used 
in CHO cell lines, and a 0.24 g/L titer of an Fc-fusion protein has been reported for this system 
(Gaillet et al., 2010). 
Expression from replicating episomes in CHO cells reduces the loss of plasmid and thereby 
prolongs the nuclear retention time of the plasmid after cell divisions (Van Craenenbroeck et al., 
2000). Episomal replication can be achieved using, e.g., the Polyomavirus large T gene (PyLT) and 
its origin of replication (PyOri) (Heffernan and Dennis, 1991), while plasmid maintenance and 
segregation can be accomplished using Epstein-Barr virus nuclear antigen-1 (EBNA-1) and its 
origin of replication (OriP) (Lupton and Levine, 1985; Yates et al., 1984). Using these two sets of 
complementing viral components, the episomal platform was reported to increase and prolong TGE 
yields of a growth hormone and MAb in CHO cells in comparison to non-replicating plasmid 
controls (Codamo et al., 2011; Kunaparaju et al., 2005). Without antibiotic-based selection, 
expression from replication-proficient episomes can be regarded only as a quasi-stable gene 
expression platform, as episomes eventually will be lost with a half-life of approximately 8-9 days 
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(Silla et al., 2006). Without selection, titers of up to 2 g/L MAb have been reported (Daramola et 
al., 2014). However, if antibiotic-based selection is applied, a stable pool of cells can be obtained 
that stably replicates and segregate episomes for more than two months (Silla et al., 2006). Thus, 
when combined with selection, the system can be regarded as stable episomal expression (SEE). 
Although all the described expression systems have been used successfully to express r-
proteins in CHO cells, each expression platform has advantages and disadvantages when used for 
effector gene expression. In Table 2, four selected expression systems are compared as platforms 
for analysing how effector genes affect qp. It is important to note that other expression systems are 
available – such as stable pools and monoclonal cell lines obtained by lentiviral vector-mediated 
gene transfer (Oberbek et al., 2011) or stable pools obtained by piggyBac transposons (Matasci et 
al., 2011). In addition, the four expression systems can be combined in different ways – such as 
using IE (Chung et al., 2004) or TGE (Hayes et al., 2010) in a monoclonal stable producer cell line. 
Nevertheless, the selected expression platforms serve to highlight important aspects to consider 
when choosing a platform and interpreting the final data. 
Duration – from transfection to answer: The preparation of plasmids carrying effector and r-
protein genes takes approximately the same time for all four expression platforms. However, the 
time span from transfection to an answer varies substantially. TGE is clearly the fastest track, as 
experiments are typically done within two to three days (Hansen et al., 2015; Johari et al., 2015; Ku 
et al., 2008). SEE is also relatively fast, as antibiotic-based selected SEE cells can be obtained 
within two weeks (Silla et al., 2006). In contrast, both IE and SGE platforms require generation and 
characterization of monoclonal cell lines that take months to perform (Noh et al., 2013).  
Gene dosage and combining genes: In terms of gene dosage titration (Rajendra et al., 2012) 
and combining genes (Nishimiya et al., 2013), TGE offers complete flexibility, as a variety of 
different plasmids (filler plasmid and/or plasmids carrying different effector genes) can be co-
expressed. This is not the case for SEE, as the copy numbers of two plasmids with different genes 
expressed, in some cases, will drift towards selection for the plasmid/gene giving rise to the lowest 
fitness cost (personal communication with Dr Mikael Rørdam Andersen, Technical University of 
Denmark). To avoid this drift, the r-protein gene and effector gene must be co-expressed from the 
same plasmid. Relatively few cell lines are manageable to maintain in parallel, which decreases the 
throughput of gene combinations for the IE and SGE platforms. Because the effector gene is 
constitutively expressed in the described IE and SGE platforms (Table 2), the effector gene dosage 
is not titratable in these platforms. Notably, recent advances in promoter engineering in CHO cells 
make it possible to precisely control the gene dosage in TGE and possibly also in SEE, IE and SGE 
platforms spanning over two orders of magnitude (Brown et al., 2014). 
Transfection stress and variability: A considerable drawback of TGE is the cytotoxic effect 
from transfection, here termed ‘transfection stress’ (Fig. 2). Different transfection reagents induce 
different levels of cytotoxicity in terms of impeded cell growth rate and a drop in viability (our own 
unpublished observations), as well as the inhibition of protein synthesis (Underhill et al., 2003). 
Notably, transfection stress can be reduced through process or cell engineering optimization (Johari 
et al., 2015; Macaraeg et al., 2013; Majors et al., 2008). In addition, variability in transfection 
efficiency is an inherent problem for TGE (Hansen et al., 2015; Liu et al., 2008); however, 
optimization and selection of the appropriate method can reduce variability substantially (Davies et 
al., 2013). For the SEE, IE and SGE platforms, transfection stress is most likely not an issue 
because of the lengthy (≥2 weeks) antibiotic-based selection processes. 
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ER stress: The expression of r-proteins is inducible for the TGE (transfection) and IE (addition 
of inducing agents) platforms. In contrast, r-proteins are constitutively expressed during the 
selection processes in the SEE and SGE platforms. Whereas the effector gene and the r-protein are 
co-expressed during the selection process in the SEE platform, the r-protein is typically first 
integrated into the genome (monoclonal cell line; Fig. 2) and subsequently the effector gene 
(quasi/mono-monoclonal cell line; Fig. 2) in the SGE platform. Thus, in contrast to the TGE, IE and 
SEE platforms, the SGE platform subjects cells to ER stress before investigating whether the 
effector gene of interest can alleviate the ER stress originating from r-protein expression. In other 
words, some cells with a high r-protein expression level and consequently a high level of ER stress 
will likely not survive during the selection processes (Hu et al., 2013) (Fig. 3B). These highly 
relevant, stressed cells will therefore not be part of the effector gene test case, in contrast to the 
TGE and IE platforms. This could introduce a bias towards cells with lower level of ER stress or 
cells inherently capable of coping with high levels of ER stress. It is important to note that stable 
producer cells adapted to a permanent increase in ER stress levels can be obtained (Sommeregger et 
al., 2016); however, the ER stress levels in these clones are not high enough to induce apoptosis. 
Instead, conditions with pro-apoptotic levels of ER stress are more likely to be established by TGE 
and IE because of the inducible nature of the two systems. Notably, the SEE platform does not 
allow for pro-apoptotic levels of ER stress to persist throughout the selection process. However, it 
does enable an effector gene of interest to alleviate pro-apoptotic levels of ER stress, because the 
effector gene and r-protein are co-expressed throughout the entire process. 
Secretion bottleneck: Post-transcriptional and secretion bottlenecks have been reported in CHO 
cells for TGE (Johari et al., 2015; Ku et al., 2008) and SGE platforms (O’Callaghan et al., 2010). 
To the best of the authors’ knowledge, a secretion bottleneck has not been reported in CHO cells for 
IE platforms, which likely is a result of a presumably low transcription rate of the r-protein gene 
compared to the TGE and SGE platforms. Naturally, the occurrence of a secretion bottleneck is 
protein-specific, and it is likely that, for some difficult-to-express proteins, a secretion bottleneck 
can be readily obtained. A post-transcriptional bottleneck in CHO cells has been reported upon 
expression from replicating episomes (Pybus et al., 2014); however, this was without antibiotic-
based selection and is therefore not regarded as SEE (Table 2). A relatively high average qp (10 pcd 
for MAbs) can be obtained using the SEE platform (personal communication with Dr Meelis 
Kadaja, Icosagen Cell Factory Ltd, Estonia), implying that post-transcriptional and/or secretion 
bottleneck conditions can be established using the SEE platform.  
Clonality and clonal variation: When using TGE and SEE platforms, a representative pool of 
cells from the host cell line is being tested (polyclonality), whereas clonally derived cells are 
typically used in the IE and SGE platforms (monoclonality). Whilst polyclonal cells represent an 
average phenotype of all cells in the host cell line, monoclonal cell lines typically represent a 
favoured phenotype identified within the functionally heterogeneous pool of cells (Fig. 2). Thus, 
different questions are being put forward when expressing effector genes in polyclonal and 
monoclonal cells. If qp is increased upon effector gene expression in polyclonal cells, this finding 
can likely be transferred to the majority of cells within the host cell line. This is not necessarily the 
case for clonally derived cell lines expressing effector genes (mono-monoclonal; see section 3). 
Thus, findings from a clonally derived cell line might be conditional; that is, the effect only applies 
to the cell line in question (O’Callaghan et al., 2010). 
Validation: Since SGE is the preferred production platform for therapeutic proteins in the 
industry (Noh et al., 2013), any effector gene should preferably be validated in a SGE context – that 
is, in high-producer monoclonal cell lines. For example, effects obtained from TGE are sometimes 
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transferable to a SGE context (Tastanova et al., 2015) and sometimes not (Mohan and Lee, 2010). 
The need for validation is obviously a drawback of the TGE, SEE and IE platforms. However, if 
measures described here are taken – such as applying different effector gene doses and establishing 
conditions with and without post-transcriptional and/or secretion bottlenecks – the success rate of 
validating effector genes is likely to increase. 
In summary, TGE is the preferred platform for screening effector genes because effector genes 
can readily be combined, gene dosage can easily be titrated and post-transcriptional and/or secretion 
bottlenecks can be obtained; in addition, TGE is not hampered by clonal variation and adaptation to 
ER stress (Table 2). A considerable drawback is the presence of transfection stress and transfection 
variability, which, however, can be addressed to some extent through process optimization. Once 
combinations of effector genes and gene doses have been identified, they need to be validated, 
preferably in multiple stable mono-monoclonal cell lines derived from different host cell lines. 
 
8. Product quality 
Although volumetric productivity and qp are important measures, the ability to enhance product 
quality is equally important in the biopharmaceutical industry (Gramer, 2014). Volumetric 
productivity is the mass of produced r-protein per volume per culture time in cell-free supernatants. 
However, a significant fraction of the protein mass can be misfolded or incorrectly processed 
variants of the r-protein (Kunert and Reinhart, 2016). In such cases where product quality is 
impaired, an increase in product titer does not necessarily correlate with an increase in the yield of 
bioactive r-protein. Quality attributes defining the overall product quality are molecularly diverse 
features of the r-protein, such as misfolding/aggregation, incorrectly processed propeptides, 
enzymatic degradation and amino acid sequence variations (Gramer, 2014). Moreover, 
glycosylation is probably the most important quality attribute of therapeutic glycoproteins, because 
the pharmacokinetic effects of undesired glycosylation patterns can be decreased drug efficacy or 
increased antigenicity (Bertozzi et al., 2009; Butler and Spearman, 2014). Recent advances in 
glycoengineering and descriptions of how effector genes can be used to modulate glycosylation 
have been described in recent reviews (Bennun et al., 2016; Dicker and Strasser, 2015; Spahn and 
Lewis, 2014). Because of scope limitations, only misfolding/aggregation and propeptide processing 
in relation to effector genes will be described here. 
Some secreted proteins are expressed as inactive proprotein precursors containing one or more 
inhibitory propeptides that need to be proteolytically cleaved off by propeptidases before full 
activity is achieved (Wiederanders et al., 2003). Since these propeptides in general are essential for 
protein folding (Chen and Inouye, 2008), propeptide-containing r-proteins need to be expressed as 
proproteins to prevent misfolding and degradation. However, there are multiple examples of 
insufficient cleavage of propeptides of r-proteins expressed CHO cells, leading to the secretion of a 
mixture of inactive proprotein and mature, correctly processed r-protein (Preininger et al., 1999; 
Sathyamurthy et al., 2015, 2012; Wasley et al., 1993). In these studies, the ectopic expression of 
effector genes encoding propeptidases increased the percentage of correctly processed r-proteins. 
This demonstrates that the propeptidase machinery within CHO cells can be the bottleneck for the 
production of propeptide-containing r-proteins. Solving this type of bottleneck is unique to 
propeptide-containing r-proteins and is therefore not generally applicable for enhancing qp of other 
types of r-proteins.  
Product quality in terms of misfolding and aggregation is intimately linked to the secretory 
pathway. Schröder et al. (2002) demonstrated that increasing the r-protein expression level of 
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antithrombin III through gene amplification in stable clonally derived CHO cells gave rise to the 
formation of disulphide-bonded aggregates. Similarly, lowering the gene dosage when transiently 
expressing an Fc-fusion protein in HEK cells has also been shown to reduce aggregate formation 
(Estes et al., 2015). In the PDI example (Table 1), the product quality has been investigated in only 
one of eleven examples. Here, a 1.2-fold increase in qp of an Fc-fusion protein was observed upon 
PDI overexpression (Johari et al., 2015). However, PDI overexpression was found to impair product 
quality through a 1.4-fold increase in the formation of high molecular aggregates. Thus, the overall 
effect of PDI overexpression was a decrease in the number of correctly folded Fc-fusion protein 
molecules produced per cell per unit time. This study elegantly illustrates the importance of 
analysing quality attributes when studying how effector genes affect qp. 
 
9. Concluding remarks and future directions 
A desirable goal of engineering the secretory capacity of CHO cells is to generate a universally 
competent cell line (‘super-CHO’) capable of manufacturing all r-proteins in demand. In general, 
this seems difficult to achieve because of product specificity (McLeod et al., 2011). For example, it 
has been reported that host cell line subclones being able to produce a MAb at relatively high qp 
levels compared to the host cell pool were not able to produce high levels of an Fc-fusion protein 
(O’Callaghan et al., 2015). Moreover, two similar antibody fragments have been shown to 
differentially influence the cell’s physiology in terms of different proteomic responses in a product-
specific manner (Sommeregger et al., 2016). Similarly, effector genes have been shown to increase 
qp in a MAb-variant-specific manner (Pybus et al., 2014). However, some effector genes can 
increase qp for different types of r-proteins in CHO cells. For example, XBP-1S was able to increase 
qp and/or product titer for secreted embryonic alkaline phosphatase (SEAP) and vascular endothelial 
growth factor (VEGF) (Tigges and Fussenegger, 2006), EPO (Ku et al., 2008), MAb (Becker et al., 
2008; Cain et al., 2013; Pybus et al., 2014), an Fc-fusion protein (Johari et al., 2015) and α1-
antitrypsin and C1 esterase inhibitor (Hansen et al., 2015). Similarly, YY1 expression was able to 
increase product titer for SEAP, VEGF and MAb (Tastanova et al., 2015). This type of general 
effector genes seems to be able to traverse product specificity. It is important to note that general 
effector genes most likely also will fall short when it comes to r-proteins that require specialised 
modifications, such as the cleavage of propeptides (Sathyamurthy et al., 2015) and γ-carboxylation 
of clotting factors (Kumar, 2015). Thus, positive effects of general effector genes are likely not 
generally valid per se, but the effect may be retrieved once specialized post-translation 
modifications are no longer constituting a bottleneck. 
The function of proteins encoded by general effector genes is probably conceptually different 
compared to effector gene-encoded proteins with more product-type specific effects (i.e. not general 
effector genes). In order to traverse product-specificity, the effect of general effector genes is 
probably multifaceted. Such multifaceted effects can be the result of simultaneously changing the 
expression level of several genes. Several cellular processes and/or molecules are able to confer 
such effects; for example phosphorylation (Rajesh et al., 2015), microRNAs (Barron et al., 2011; 
Hackl et al., 2012), transcription factors (Adachi et al., 2008; Harding et al., 2003) and histone 
marks (Dahodwala and Sharfstein, 2014). The molecules involved in these processes do not interact 
directly with the r-protein and the effects are therefore indirect (Fig. 1). An attractive advantage of 
using general effector genes is the possibility of modulating the expression level of more genes than 
is currently possible when co-expressing multiple single effector genes. However, some effects 
from general effector genes may also be adverse due to pleiotropic, undesired regulation of a subset 
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of genes (Stearns, 2010). Thus, investigating and eliminating these potential adverse effects of a 
general effector gene of interest may improve the desired phenotype. 
Although single general effector genes seem to be part of the answer, multiple (general) 
effector genes are likely a more coherent and robust solution for increasing the secretory capacity 
(Harreither et al., 2015; Seth et al., 2007). In fact, multiple reactions within the biosynthetic 
pathway of MAb seem amenable for improvement (O’Callaghan et al., 2010). This notion is 
supported by non-limiting examples of studies demonstrating an increase in volumetric productivity 
or qp in CHO cells upon the expression of effector genes related to translation and translocation (Le 
Fourn et al., 2014), ER folding processes (Borth et al., 2005; Chung et al., 2004; Hwang et al., 
2003) and protein transport and secretion (Florin et al., 2009; Peng et al., 2011; Peng and 
Fussenegger, 2009) (Fig. 1). Several reports have demonstrated synergistic effects on the 
volumetric productivity or qp of co-expressing multiple genes in CHO cells (Cain et al., 2013; Le 
Fourn et al., 2014; Mohan and Lee, 2010; Peng and Fussenegger, 2009), demonstrating the potential 
of combining effector genes. In addition to effector gene overexpression, downregulating 
endogenous genes might be equally important for increasing qp (Feichtinger et al., 2016; Harreither 
et al., 2015). Finally, supplementing small-molecule chemical chaperones combined with effector 
gene overexpression has been shown to exceed the limits of functional heterogeneity present in the 
CHO-S host cell line (Johari et al., 2015). 
When modulating the expression of multiple effector genes, the relative stoichiometry between 
gene transcripts (gene dosage) becomes an important aspect to consider to obtain an optimal effect 
on qp (Xiao et al., 2014). However, qp is not the only relevant factor: the time integral of viable cell 
density (accumulated viable cell number) and product quality attributes are important measures to 
control in production bioprocesses for increasing the product yield (Gramer, 2014; Kim et al., 
2012). This is not a simple task, because process parameters (for example metabolite concentration 
and osmolality) in a bioreactor can change throughout a bioprocess (Justice et al., 2011). These 
dynamic changes affect the overall physiology and fitness of the cell and are likely to affect 
transcription rates in a promoter-specific manner (Brown and James, 2015). Such bioprocess-
dependent variables can therefore interfere with the gene dosage of single and multiple effector 
genes. Thus, highly context-specific promoter designs are needed to simultaneously control the 
expression level of multiple effector genes during production bioprocesses (see recent review 
(Brown and James, 2015)). In combination with improved designs of vector elements, site-specific 
integration of expression cassettes into so-called safe harbour sites (Papapetrou et al., 2011) in the 
CHO genome has the potential of enabling predictable and stable expression levels of effector genes 
in clonally derived cell lines. Based on the game-changing CRISPR-Cas9 technology (Mali et al., 
2013), site-specific integration into CHO cells is now possible at a relatively low cost with 
applicable efficiencies (Lee et al., 2016, 2015). 
The global cellular view of systems biology and ’omics-based approaches holds a unique 
potential to identify pathways and gene networks comprising novel effector genes (Datta et al., 
2013; Gutierrez and Lewis, 2015; Kildegaard et al., 2013). These networks would most likely be 
tedious to identify using a classical reductionist’s approach where typically only a few genes are 
being tested. Indeed, as recently stated by Clarke and Lee (2014), the CHO community is currently 
generating ’omics data at an ever-increasing rate. This is supported by the following non-exhaustive 
examples on CHO ’omics studies: genomics (Lewis et al., 2013; Xu et al., 2011), transcriptomics 
(Becker et al., 2011; Doolan et al., 2008), translatomics (Courtes et al., 2013), proteomics (Baycin-
Hizal et al., 2012; Carlage et al., 2009), metabolomics (Selvarasu et al., 2012; Zang et al., 2011) and 
integrative ’omics (Clarke et al., 2012). Moreover, a consensus genome-scale reconstruction of 
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CHO cell metabolism has now been established (Hefzi et al., 2016) which potentially opens up new 
designs of CHO cell lines (Kaas et al., 2014). In fact, using the genome-scale model to assess 
resource utilization suggests modulating expression of effector genes related to the secretory 
pathway is a more efficient way of improving qp compared to typical bioprocess treatments such as 
sodium butyrate and hypothermia (Hefzi et al., 2016). 
As mentioned by Hussain et al. (2014), some CHO ’omics studies were probably hampered by 
clonal variation (Fig. 2), because only a few monoclonal cell lines were compared. As previously 
described, CHO cells – even within a host cell line – are functionally and genomically diverse and 
only a fraction of the cells are universally competent in terms of r-protein production (O’Callaghan 
et al., 2010). Moreover, the ‘omics profile of gene-amplified clonally derived high producer cells 
are probably vastly different compared to before transfection, due to, for example, adaption to ER 
stress. Thus, an ’omics profile of a high producer might comprise information on the end point of 
coping with a high secretion load. However, the profile does not necessarily contain any 
information on the cellular mechanism(s) involved in coping with the initial secretion load that the 
cell is subjected to right after transfection and/or gene amplification events. Instead, the intrinsic 
capability for coping with the initial secretion load is more likely to be found in non-transfected 
cells (non-adapted cells; Fig. 2). In fact, Harreither et al. (2015) were able to show that the 
capability to obtain high qp from transient expression is reflected in the native transcriptome of host 
cell line subclones. Besides being a potential source of novel candidate effector genes, ’omics-based 
profiling of non-adapted monoclonal cells holds the potential to give fundamental insight into the 
functional heterogeneity of CHO cells. 
Historically, the CHO lineage was not generated for r-protein production but for the 
investigation of molecular and classical cell genetics (Wurm, 2013). Moreover, CHO cells do not 
originate from dedicated secretory tissues like plasma cells and β-cells. By default, CHO cells 
therefore seem to be a suboptimal cell line for r-protein production, with many opportunities for 
improvement. The significant advances achieved through the ectopic expression of effector genes 
(Fischer et al., 2015) are likely only the tip of the iceberg, as relatively few of the approximately 
20,000 genes in the Chinese hamster genome (Kremkow et al., 2015; Lewis et al., 2013) have been 
investigated. Furthermore, combining effector genes increases the number of possible test 
conditions dramatically. However, the number of possible test conditions can be reduced through 
systems biology- and ‘omics-based approaches. Despite valuable guidance from systems biology, 
several novel effector genes (single genes and combinations) remain to be investigated. In 
conclusion, the cellular and experimental factors described here will likely aid future investigations 
of effector genes and thereby accelerate the development of CHO cell lines with optimized 
secretory capacity. 
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Tables 
Table 1. Studies on how ectopic expression of protein disulphide isomerase (PDI) affects volumetric productivity or qp of r-proteins in 
CHO cells. 
r-protein 
and 
reference 
r-protein 
expression
a
; 
clonality
b
 
Post-
transcripti
onal 
bottleneck 
Orig
in of 
PDI 
PDI 
expression
a
; 
clonality
c
 
Gene 
dosage 
Host cell; 
cell culture 
Effect on titer/qp 
Interleukin-
15 
(Davis et al., 
2000) 
SGE; 1 
monoclonal 
cell line 
Not 
investigated 
Hum
an 
SGE; quasi-
polyclonal 
Single gene 
dose  
CHO-
DXB11; 2-3 
days batch 
culture 
No effect 
Fc-fusion 
protein 
(Davis et al., 
2000) 
Stable 
expression; 1 
monoclonal 
cell line 
Not 
investigated 
Hum
an 
SGE; quasi-
polyclonal and 3 
mono-
monoclonal cell 
lines 
3 clones 
with 
different 
levels of 
PDI 
expression  
CHO-
DXB11; 2-3 
days batch 
culture 
Polyclonal: No effect 
Mono-monoclonal: 2-
fold decrease in titer for 
clone with highest PDI 
expression 
MAb 
(Borth et al., 
2005) 
SGE; 1 
monoclonal 
cell line 
Not 
investigated 
Not 
re-
porte
d 
SGE; quasi-
polyclonal 
Single gene 
dose  
CHO dhfr
- 
; 3 
days batch 
culture 
1.37-fold increase in qp 
Thrombopoie
tin 
(Mohan et al., 
2007) 
SGE; 1 
monoclonal 
cell line 
Not 
investigated 
CH
O 
IE; 2 mono-
monoclonal cell 
lines 
Single gene 
dose 
CHO-
DXB11; 3 
days batch 
culture 
No effect 
MAb 
(Mohan et al., 
2007) 
SGE; 1 
monoclonal 
cell line 
Not 
investigated 
CH
O 
IE; 2 mono-
monoclonal 
lines 
Single gene 
dose 
DG44; 2 
days batch 
culture 
1.15–1.27-fold increase 
in qp 
MAb 
(Hayes et al., 
2010) 
SGE; 1 
monoclonal 
cell line 
Not 
investigated 
Hum
an 
TGE; 1 mono-
monoclonal line 
Single gene 
dose  
CHO-K1SV; 
2 days batch 
culture 
No effect 
MAb (4 
variants) 
TGE 
(episomal-
Yes 
(predicted 
Hum
an 
TGE; polyclonal Single gene 
dose 
CHO-K1 
EB27; 10 
No effect for 3 variants 
and 1.3-fold increase in 
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(Pybus et al., 
2014) 
replication); 
polyclonal 
by 
modelling) 
days fed-
batch culture 
qp for 1 variant. 
Fc-fusion 
protein 
(Johari et al., 
2015) 
TGE; 
polyclonal 
Yes Hum
an 
TGE; polyclonal 3 gene doses CHO-S; 3 
days batch 
culture 
Gene dosage/effect on 
qp: 10%/no effect, 
20%/1.2-fold increase 
(1.4-fold increase in 
aggregate formation), 
40%/1.3-fold increase.  
α1-antitrypsin 
(Hansen et 
al., 2015) 
TGE; 
polyclonal 
Not 
investigated 
Mou
se 
TGE; polyclonal Single gene 
dose 
CHO-S; 3 
days batch 
culture 
1.2-fold decrease in qp 
C1 esterase 
inhibitor 
(Hansen et 
al., 2015) 
TGE; 
polyclonal 
Not 
investigated 
Mou
se 
TGE; polyclonal Single gene 
dose 
CHO-S; 3 
days batch 
culture 
1.6-fold decrease in qp 
MAb 
(Our 
unpublished 
data) 
TGE; 
polyclonal 
Not 
investigated 
Mou
se 
TGE; polyclonal Single gene 
dose 
CHO-S; 3 
days batch 
culture 
1.3-fold decrease in qp 
a)
 For definition and abbreviation of expression platforms, see Table 2. 
b) 
Clonality of cells expressing the r-protein before transfection of the effector gene (SGE). r-proteins and effector genes are co-expressed in 
TGE platforms (polyclonal). For definition of clonality, see Figure 2. 
c) 
Clonality of cells expressing PDI. For definition of clonality, see Figure 2. 
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Table 2. Selected expression platforms available for analysing how effector genes affect qp in CHO 
cells.  
 Transient gene 
expression 
(TGE)
a
 
Stable 
episomal 
expression 
(SEE)
b
 
Inducible 
expression 
(IE)
c
 
Stable gene 
expression 
(SGE)
d
 
Time from transfection to 
answer: 
2-3 days
e
 ~2 weeks >2 months >2 months 
Gene dosage easily titrated: Yes No Yes No 
Genes easily combined: Yes No No No 
Transfection stress and 
variability: 
Yes No No No 
Cells adapted to ER stress: No (No)
f
 No Yes 
Secretion bottleneck easily 
obtained: 
Yes (Yes)
g 
No Yes 
Clonality: Polyclonal Polyclonal Mono-
monoclonal
h
 
Mono-
monoclonal
h
 
Clonal variation: No No Yes Yes 
Validation by SGE needed: Yes Yes Yes No 
a)
 Transient, plasmid-based co-expression of r-protein and effector genes. Examples: (Hansen et al., 
2015; Johari et al., 2015; Ku et al., 2008; Tastanova et al., 2015). 
b) 
Stable episomal co-expression of r-protein and effector genes after antibiotic-based selection 
(without selection resembles TGE). No published examples of co-expression are available, but the 
expression system is described here: (Kunaparaju et al., 2005; Silla et al., 2006). The r-protein gene 
and effector gene must be co-expressed from the same plasmid to prevent a drift in copy number 
between the two genes (see ‘Gene dosage and combining genes’ in section 7 for details). 
c) 
Inducible expression of a stably integrated gene encoding the r-protein in a clonally derived cell 
line constitutively expressing an effector gene of interest. No reported examples of this specific 
setup are available to the best of the authors’ knowledge, but examples of the expression system are 
described here: (Mohan et al., 2007; Mohan and Lee, 2010). 
 
d) 
Constitutive (stable) co-expression of stably integrated genes encoding r-protein and effector 
genes in clonally derived cell lines. Examples: (Dreesen and Fussenegger, 2011; Haredy et al., 
2013; Tastanova et al., 2015). 
e)
 Features regarded as advantages are highlighted in boldface type. 
f)
 See ‘ER stress’ in section 7 for details. 
g)
 See ‘Secretion bottleneck’ in section 7 for details. 
h)
 Quasi-polyclonal cell lines can also be used; however, mono-monoclonal cell lines are commonly 
used. For definition of quasi-polyclonal and mono-monoclonal cell lines, see Fig. 2. 
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Figure legends 
Figure 1. Cellular and experimental factors affecting the biosynthetic pathway of r-proteins in 
CHO cells. Graphical representation of a CHO cell co-expressing an r-protein (gene, mRNA, 
polypeptide and protein in red letters) and an effector gene (gene and protein in blue letters). Effects 
from external factors are indicated with dashed arrows. Effector protein-mediated effects are shown 
with thin line arrows, and whether these effects are direct or indirect through interactions with an 
unknown DNA or protein element (element X) are illustrated. Nucleus, ER, Golgi and transport 
vesicles are depicted in the upper half of the cell. Since localization of effector proteins is gene-
dependent, cytoplasmic organelles are not depicted in the lower half of the cell. PTM, post-
translational modification. 
 
Figure 2. Clonal variation in stable CHO cell lines. A typical process of generating a clonally 
derived stable CHO cell line co-expressing an r-protein and an effector gene is illustrated. CHO 
cells are depicted as circles, and the red circle is a high-producer cell clone selected for transfection 
of the effector gene. To depict the heterogeneity within the cell pools, the qp level of each cell is 
illustrated as black and grey pie charts for transient and constitutive expression of the r-protein, 
respectively. Clonality of each phase is indicated. Quasi-polyclonal and mono-monoclonal mean 
that the polyclonal cell line and monoclonal cell line, respectively, both originate from a 
monoclonal r-protein producer cell line. Whether cells have adapted to expression of the r-protein is 
indicated (see ‘ER stress’ in Table 2). The extent of clonal variation throughout the process is 
depicted and is defined as the possible phenotypic difference from an average cell in the host cell 
line. Transfection-mediated stress is depicted (see ‘Transfection stress’ in Table 2). SCS: single-cell 
sorting. 
 
Figure 3. Secretion bottleneck and ER stress. A) Schematic depiction of a secretion bottleneck 
upon co-expression of an r-protein and an effector gene. The black solid line shows the relationship 
between translation rate of an r-protein and qp. The grey solid line illustrates that expression of 
certain effector genes gives rise to a positive effect on qp only when a secretion bottleneck is 
present. The grey and black dashed lines indicate the onset translation rate for a secretion bottleneck 
with and without expression of a qp-increasing effector gene, respectively. B) Schematic graph 
showing how secretion bottlenecks affect ER stress levels. Same colour code as in panel A is used 
except for the red line, which indicates the threshold between anti- and pro-apoptotic ER stress 
levels. 
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